Newswise—A new study published in Circulation, a peer-reviewed journal of the American Heart Association and led by a cardiologist at the Peter Munk Cardiac Centre at Toronto General Hospital, has found evidence that only 1 of the 21 genes normally associated with Brugada Syndrome, a serious genetic heart condition associated with the risk of sudden arrhythmic death, is a definitive cause of the condition.

"The global impact of this important research is significant for scientists, medical professionals, and patients who are genetically predisposed or who have been diagnosed with this potentially fatal heart condition," says Dr. Barry Rubin, Medical Director, Peter Munk Cardiac Centre, University Health Network. "The evidence-based findings of our internationally recognized, multidisciplinary team of researchers could dramatically alter both the diagnostic and treatment pathway for patients with Brugada Syndrome as well as other genetic-based conditions."

The study's findings came as the result of evaulations conducted by the Clinical Genome Resource (ClinGen) expert panel led by Dr. Michael Gollob, cardiologist, Peter Munk Cardiac Centre and Chair, Peter Munk Centre of Excellence in Molecular Medicine. ClinGen is supported by the National Institutes of Health (NIH) in the United States.

"Our research examined the genetic evidence for 21 genes reported as single-gene causes for Brugada Syndrome," says Dr. Gollob "Remarkably, 20 of 21 genes were classified as disputed evidence, indicating that genetic evidence to support causation of this disease by these specific genes was lacking," he says.

Researchers found that only the SCN5A gene, first discovered 20 years ago for Brugada Syndrome, was deemed a definitive cause of the condition. The study also highlights the risks associated with the genetic testing of genes that lack sufficient evidence for disease causation.

"Clinically, evaluating genes that lack validity for disease causality creates a risk of misinterpreting the relevance of genetic changes in these genes and may lead to inappropriate diagnostic conclusions and treatment in patients," says Dr. Gollob. "Our conclusions from this study are surely not unique to Brugada Syndrome. Invalid or questionable gene-disease associations are likely common for many diseases across multiple medical disciplines," he says.

"This ClinGen report highlights the importance and value of ClinGen's efforts to standardize and improve the databases used by laboratories to guide testing decisions and the interpretation of test results," said Jonathan Berg, MD, PhD, FACMG whose group leads the ClinGen Cardiovascular Genomics Clinical Domain Work Group under which this Expert Panel completed their work on determining which genes are actually associated with Brugada Syndrome.

Based on their findings, the authors recommend that an evidence-based evaluation of reported gene-disease associations should be completed prior to the testing of genes in patient care.